{"generated":"2026-10-03","inputs":{"factcheck":"2026-09-28","trialChanges":"2026-09-28","fda":"2026-09-30","regional":"2026-09-30"},"proposals":[{"kind":"trial-results","confidence":"high","entityId":"nct05023980","entityName":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","entityKind":"trial","route":"/trials/nct05023980/","file":"src/data/pipeline-trials-wave6.ts","line":3457,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L3457","field":"result / outcomes","current":"(none)","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT05023980 (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT05023980?tab=results","detected":"2026-09-28","id":"trial-results:nct05023980:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-results","confidence":"high","entityId":"rosella","entityName":"ROSELLA / GOG-3073","entityKind":"trial","route":"/trials/rosella/","file":"src/data/spikes/ovarian.ts","line":110,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/ovarian.ts#L110","field":"result / outcomes","current":"OS 16.0 vs 11.9 months (HR 0.69).","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT05257408 (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT05257408?tab=results","detected":"2026-09-28","id":"trial-results:rosella:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-results","confidence":"high","entityId":"nct05471843","entityName":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","entityKind":"trial","route":"/trials/nct05471843/","file":"src/data/pipeline-trials-wave5.ts","line":1537,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1537","field":"result / outcomes","current":"(none)","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT05471843 (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT05471843?tab=results","detected":"2026-09-28","id":"trial-results:nct05471843:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-status","confidence":"medium","entityId":"bonner-cetuximab-rt","entityName":"Bonner trial (cetuximab plus radiotherapy)","entityKind":"trial","route":"/trials/bonner-cetuximab-rt/","file":"src/data/radiation-wave4.ts","line":60,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/radiation-wave4.ts#L60","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT00004227","id":"trial-status:bonner-cetuximab-rt:status:withdrawn","detected":"2026-10-03"},{"kind":"trial-status","confidence":"medium","entityId":"clocc","entityName":"CLOCC","entityKind":"trial","route":"/trials/clocc/","file":"src/data/spikes/colorectal-treatment-trials-advanced.ts","line":218,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-treatment-trials-advanced.ts#L218","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT00043004","id":"trial-status:clocc:status:withdrawn","detected":"2026-10-03"},{"kind":"trial-status","confidence":"medium","entityId":"cyto-pv","entityName":"CYTO-PV","entityKind":"trial","route":"/trials/cyto-pv/","file":"src/data/polycythaemia-vera.ts","line":70,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/polycythaemia-vera.ts#L70","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT01645124","id":"trial-status:cyto-pv:status:withdrawn","detected":"2026-10-03"},{"kind":"trial-status","confidence":"medium","entityId":"destiny-lung01","entityName":"DESTINY-Lung01","entityKind":"trial","route":"/trials/destiny-lung01/","file":"src/data/trials-subtypes-wave.ts","line":46,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/trials-subtypes-wave.ts#L46","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT03505710","id":"trial-status:destiny-lung01:status:withdrawn","detected":"2026-10-03"},{"kind":"trial-status","confidence":"medium","entityId":"keynote-057","entityName":"KEYNOTE-057","entityKind":"trial","route":"/trials/keynote-057/","file":"src/data/trials-subtypes-wave.ts","line":745,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/trials-subtypes-wave.ts#L745","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT02625961","id":"trial-status:keynote-057:status:withdrawn","detected":"2026-10-03"},{"kind":"trial-status","confidence":"medium","entityId":"rockstar","entityName":"ROCKstar","entityKind":"trial","route":"/trials/rockstar/","file":"src/data/issues-2026-09-wave-a.ts","line":124,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/issues-2026-09-wave-a.ts#L124","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT03640481","id":"trial-status:rockstar:status:withdrawn","detected":"2026-10-03"},{"kind":"trial-status","confidence":"medium","entityId":"tower","entityName":"TOWER","entityKind":"trial","route":"/trials/tower/","file":"src/data/spikes/all-leukemia.ts","line":115,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/all-leukemia.ts#L115","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT02013167","id":"trial-status:tower:status:withdrawn","detected":"2026-10-03"},{"kind":"drug-approval","confidence":"medium","entityId":"aspirin","entityName":"Aspirin","entityKind":"drug","route":"/drugs/aspirin/","file":"src/data/essential-thrombocythaemia.ts","line":76,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/essential-thrombocythaemia.ts#L76","field":"approvals / status","current":"status established; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Aspirin\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:aspirin:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-03"},{"kind":"drug-approval","confidence":"medium","entityId":"danazol","entityName":"Danazol","entityKind":"drug","route":"/drugs/danazol/","file":"src/data/drugs-subtypes-wave.ts","line":247,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/drugs-subtypes-wave.ts#L247","field":"approvals / status","current":"status established; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Danazol\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:danazol:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-03"},{"kind":"drug-approval","confidence":"medium","entityId":"givinostat","entityName":"Givinostat","entityKind":"drug","route":"/drugs/givinostat/","file":"src/data/drugs-pipeline-wave1.ts","line":545,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/drugs-pipeline-wave1.ts#L545","field":"approvals / status","current":"status phase-3; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Givinostat\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:givinostat:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-03"},{"kind":"drug-approval","confidence":"medium","entityId":"ivermectin","entityName":"Ivermectin","entityKind":"drug","route":"/drugs/ivermectin/","file":"src/data/ivermectin.ts","line":65,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/ivermectin.ts#L65","field":"approvals / status","current":"status phase-2; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Ivermectin\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:ivermectin:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-03"},{"kind":"drug-approval","confidence":"medium","entityId":"metyrapone","entityName":"Metyrapone","entityKind":"drug","route":"/drugs/metyrapone/","file":"src/data/drugs-subtypes-wave.ts","line":161,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/drugs-subtypes-wave.ts#L161","field":"approvals / status","current":"status established; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Metyrapone\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:metyrapone:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-03"},{"kind":"drug-approval","confidence":"medium","entityId":"mifepristone","entityName":"Mifepristone","entityKind":"drug","route":"/drugs/mifepristone/","file":"src/data/drugs-subtypes-wave.ts","line":101,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/drugs-subtypes-wave.ts#L101","field":"approvals / status","current":"status negative; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Mifepristone\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:mifepristone:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-03"},{"kind":"drug-approval","confidence":"medium","entityId":"nicotinamide","entityName":"Nicotinamide","entityKind":"drug","route":"/drugs/nicotinamide/","file":"src/data/drugs-subtypes-wave.ts","line":40,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/drugs-subtypes-wave.ts#L40","field":"approvals / status","current":"status established; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Nicotinamide\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:nicotinamide:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-03"},{"kind":"drug-approval","confidence":"medium","entityId":"pancrelipase","entityName":"Pancrelipase (pancreatic enzyme replacement therapy)","entityKind":"drug","route":"/drugs/pancrelipase/","file":"src/data/spikes/pancreatic-treatment.ts","line":59,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/pancreatic-treatment.ts#L59","field":"approvals / status","current":"status established; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Pancrelipase\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:pancrelipase:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-03"},{"kind":"trial-status","confidence":"medium","entityId":"nct06754085","entityName":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","entityKind":"trial","route":"/trials/nct06754085/","file":"src/data/pipeline-trials-wave6.ts","line":4519,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L4519","field":"status","current":"recruiting","proposed":"completed","evidence":"ClinicalTrials.gov overall status is COMPLETED; recorded recruiting. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT06754085","id":"trial-status:nct06754085:status:completed","detected":"2026-10-03"},{"kind":"trial-completion","confidence":"medium","entityId":"nct02650401","entityName":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","entityKind":"trial","route":"/trials/nct02650401/","file":"src/data/pipeline-trials-wave6.ts","line":4987,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L4987","field":"yearReported / calendar","current":"2026-06-30","proposed":"2027-06-30","evidence":"Primary completion date moved from 2026-06-30 to 2027-06-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT02650401","detected":"2026-09-28","id":"trial-completion:nct02650401:yearreported-calendar:2027-06-30"},{"kind":"trial-status","confidence":"medium","entityId":"nct03478488","entityName":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","entityKind":"trial","route":"/trials/nct03478488/","file":"src/data/pipeline-trials-wave6.ts","line":5665,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L5665","field":"status","current":"active","proposed":"completed","evidence":"Registry status moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT03478488","detected":"2026-09-28","id":"trial-status:nct03478488:status:completed"},{"kind":"trial-status","confidence":"medium","entityId":"nct04489771","entityName":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","entityKind":"trial","route":"/trials/nct04489771/","file":"src/data/pipeline-trials-wave6.ts","line":7945,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7945","field":"status","current":"active","proposed":"completed","evidence":"Registry status moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT04489771","detected":"2026-09-28","id":"trial-status:nct04489771:status:completed"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04590326","entityName":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata","entityKind":"trial","route":"/trials/nct04590326/","file":"src/data/pipeline-trials-wave5.ts","line":636,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L636","field":"yearReported / calendar","current":"2027-03-25","proposed":"2028-11-08","evidence":"Primary completion date moved from 2027-03-25 to 2028-11-08; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04590326","detected":"2026-09-28","id":"trial-completion:nct04590326:yearreported-calendar:2028-11-08"},{"kind":"trial-status","confidence":"medium","entityId":"nct04626479","entityName":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","entityKind":"trial","route":"/trials/nct04626479/","file":"src/data/pipeline-trials-wave6.ts","line":2167,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L2167","field":"status","current":"active","proposed":"completed","evidence":"Registry status moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT04626479","detected":"2026-09-28","id":"trial-status:nct04626479:status:completed"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04626479","entityName":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","entityKind":"trial","route":"/trials/nct04626479/","file":"src/data/pipeline-trials-wave6.ts","line":2167,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L2167","field":"yearReported / calendar","current":"2026-08-21","proposed":"2026-08-10","evidence":"Primary completion date moved from 2026-08-21 to 2026-08-10; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04626479","detected":"2026-09-28","id":"trial-completion:nct04626479:yearreported-calendar:2026-08-10"},{"kind":"trial-status","confidence":"medium","entityId":"nct04626518","entityName":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","entityKind":"trial","route":"/trials/nct04626518/","file":"src/data/pipeline-trials-wave6.ts","line":5611,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L5611","field":"status","current":"active","proposed":"completed","evidence":"Registry status moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT04626518","detected":"2026-09-28","id":"trial-status:nct04626518:status:completed"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04626518","entityName":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","entityKind":"trial","route":"/trials/nct04626518/","file":"src/data/pipeline-trials-wave6.ts","line":5611,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L5611","field":"yearReported / calendar","current":"2026-08-21","proposed":"2026-07-23","evidence":"Primary completion date moved from 2026-08-21 to 2026-07-23; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04626518","detected":"2026-09-28","id":"trial-completion:nct04626518:yearreported-calendar:2026-07-23"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04662255","entityName":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","entityKind":"trial","route":"/trials/nct04662255/","file":"src/data/pipeline-trials-wave6.ts","line":7573,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7573","field":"yearReported / calendar","current":"2027-01","proposed":"2027-11","evidence":"Primary completion date moved from 2027-01 to 2027-11; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04662255","detected":"2026-09-28","id":"trial-completion:nct04662255:yearreported-calendar:2027-11"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04924075","entityName":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL","entityKind":"trial","route":"/trials/nct04924075/","file":"src/data/pipeline-trials-wave5.ts","line":1837,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1837","field":"yearReported / calendar","current":"2029-12-27","proposed":"2032-11-18","evidence":"Primary completion date moved from 2029-12-27 to 2032-11-18; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04924075","detected":"2026-09-28","id":"trial-completion:nct04924075:yearreported-calendar:2032-11-18"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04925479","entityName":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","entityKind":"trial","route":"/trials/nct04925479/","file":"src/data/pipeline-trials-wave6.ts","line":3445,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L3445","field":"yearReported / calendar","current":"2027-09-21","proposed":"2027-09-02","evidence":"Primary completion date moved from 2027-09-21 to 2027-09-02; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04925479","detected":"2026-09-28","id":"trial-completion:nct04925479:yearreported-calendar:2027-09-02"},{"kind":"trial-completion","confidence":"medium","entityId":"majestec-3","entityName":"MajesTEC-3","entityKind":"trial","route":"/trials/majestec-3/","file":"src/data/spikes/multiple-myeloma.ts","line":205,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/multiple-myeloma.ts#L205","field":"yearReported / calendar","current":"2025-09-15","proposed":"2025-08-01","evidence":"Primary completion date moved from 2025-09-15 to 2025-08-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05083169","detected":"2026-09-28","id":"trial-completion:majestec-3:yearreported-calendar:2025-08-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05132075","entityName":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","entityKind":"trial","route":"/trials/nct05132075/","file":"src/data/pipeline-trials-wave2.ts","line":373,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L373","field":"yearReported / calendar","current":"2026-08-25","proposed":"2026-09-03","evidence":"Primary completion date moved from 2026-08-25 to 2026-09-03; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05132075","detected":"2026-09-28","id":"trial-completion:nct05132075:yearreported-calendar:2026-09-03"},{"kind":"trial-completion","confidence":"medium","entityId":"herizon-gea-01","entityName":"HERIZON-GEA-01","entityKind":"trial","route":"/trials/herizon-gea-01/","file":"src/data/spikes/gastric.ts","line":80,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/gastric.ts#L80","field":"yearReported / calendar","current":"2026-09-30","proposed":"2026-07-15","evidence":"Primary completion date moved from 2026-09-30 to 2026-07-15; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05152147","detected":"2026-09-28","id":"trial-completion:herizon-gea-01:yearreported-calendar:2026-07-15"},{"kind":"trial-completion","confidence":"medium","entityId":"rosella","entityName":"ROSELLA / GOG-3073","entityKind":"trial","route":"/trials/rosella/","file":"src/data/spikes/ovarian.ts","line":110,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/ovarian.ts#L110","field":"yearReported / calendar","current":"2025-03-24","proposed":"2025-03-31","evidence":"Primary completion date moved from 2025-03-24 to 2025-03-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05257408","detected":"2026-09-28","id":"trial-completion:rosella:yearreported-calendar:2025-03-31"},{"kind":"trial-status","confidence":"medium","entityId":"nct05287113","entityName":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","entityKind":"trial","route":"/trials/nct05287113/","file":"src/data/pipeline-trials-wave6.ts","line":49,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L49","field":"status","current":"active","proposed":"completed","evidence":"Registry status moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT05287113","detected":"2026-09-28","id":"trial-status:nct05287113:status:completed"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05528133","entityName":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","entityKind":"trial","route":"/trials/nct05528133/","file":"src/data/spikes/tnbc-registry-trials.ts","line":913,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/tnbc-registry-trials.ts#L913","field":"yearReported / calendar","current":"2028-05","proposed":"2029-09","evidence":"Primary completion date moved from 2028-05 to 2029-09; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05528133","detected":"2026-09-28","id":"trial-completion:nct05528133:yearreported-calendar:2029-09"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05552976","entityName":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W","entityKind":"trial","route":"/trials/nct05552976/","file":"src/data/pipeline-trials-wave4.ts","line":1376,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L1376","field":"yearReported / calendar","current":"2026-07-18","proposed":"2026-09-28","evidence":"Primary completion date moved from 2026-07-18 to 2026-09-28; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05552976","detected":"2026-09-28","id":"trial-completion:nct05552976:yearreported-calendar:2026-09-28"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05745740","entityName":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","entityKind":"trial","route":"/trials/nct05745740/","file":"src/data/spikes/lung-registry-trials.ts","line":716,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L716","field":"yearReported / calendar","current":"2025-12","proposed":"2027-12-01","evidence":"Primary completion date moved from 2025-12 to 2027-12-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05745740","detected":"2026-09-28","id":"trial-completion:nct05745740:yearreported-calendar:2027-12-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05752136","entityName":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma","entityKind":"trial","route":"/trials/nct05752136/","file":"src/data/spikes/colorectal-registry-trials.ts","line":3119,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-registry-trials.ts#L3119","field":"yearReported / calendar","current":"2025-04","proposed":"2026-11-01","evidence":"Primary completion date moved from 2025-04 to 2026-11-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05752136","detected":"2026-09-28","id":"trial-completion:nct05752136:yearreported-calendar:2026-11-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06005493","entityName":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","entityKind":"trial","route":"/trials/nct06005493/","file":"src/data/pipeline-trials-wave5.ts","line":3528,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3528","field":"yearReported / calendar","current":"2027-07-16","proposed":"2029-03-16","evidence":"Primary completion date moved from 2027-07-16 to 2029-03-16; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06005493","detected":"2026-09-28","id":"trial-completion:nct06005493:yearreported-calendar:2029-03-16"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06062420","entityName":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","entityKind":"trial","route":"/trials/nct06062420/","file":"src/data/pipeline-trials-wave6.ts","line":409,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L409","field":"yearReported / calendar","current":"2026-09-01","proposed":"2026-09-10","evidence":"Primary completion date moved from 2026-09-01 to 2026-09-10; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06062420","detected":"2026-09-28","id":"trial-completion:nct06062420:yearreported-calendar:2026-09-10"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06109272","entityName":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","entityKind":"trial","route":"/trials/nct06109272/","file":"src/data/pipeline-trials-wave2.ts","line":271,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L271","field":"yearReported / calendar","current":"2030-09","proposed":"2027-01","evidence":"Primary completion date moved from 2030-09 to 2027-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06109272","detected":"2026-09-28","id":"trial-completion:nct06109272:yearreported-calendar:2027-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06140836","entityName":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","entityKind":"trial","route":"/trials/nct06140836/","file":"src/data/pipeline-trials-wave6.ts","line":9410,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L9410","field":"yearReported / calendar","current":"2026-03-13","proposed":"2027-02-16","evidence":"Primary completion date moved from 2026-03-13 to 2027-02-16; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06140836","detected":"2026-09-28","id":"trial-completion:nct06140836:yearreported-calendar:2027-02-16"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06151574","entityName":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","entityKind":"trial","route":"/trials/nct06151574/","file":"src/data/pipeline-trials-wave6.ts","line":2767,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L2767","field":"yearReported / calendar","current":"2026-09-02","proposed":"2026-12-10","evidence":"Primary completion date moved from 2026-09-02 to 2026-12-10; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06151574","detected":"2026-09-28","id":"trial-completion:nct06151574:yearreported-calendar:2026-12-10"},{"kind":"trial-status","confidence":"medium","entityId":"liger-hn1","entityName":"LiGeR-HN1","entityKind":"trial","route":"/trials/liger-hn1/","file":"src/data/spikes/head-and-neck.ts","line":111,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/head-and-neck.ts#L111","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT06525220","detected":"2026-09-28","id":"trial-status:liger-hn1:status:active"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06564844","entityName":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","entityKind":"trial","route":"/trials/nct06564844/","file":"src/data/pipeline-trials-wave4.ts","line":710,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L710","field":"yearReported / calendar","current":"2027-06-30","proposed":"2026-07-10","evidence":"Primary completion date moved from 2027-06-30 to 2026-07-10; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06564844","detected":"2026-09-28","id":"trial-completion:nct06564844:yearreported-calendar:2026-07-10"},{"kind":"trial-status","confidence":"medium","entityId":"nct06601504","entityName":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","entityKind":"trial","route":"/trials/nct06601504/","file":"src/data/pipeline-trials-wave5.ts","line":162,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L162","field":"status","current":"active","proposed":"completed","evidence":"Registry status moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT06601504","detected":"2026-09-28","id":"trial-status:nct06601504:status:completed"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06601504","entityName":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","entityKind":"trial","route":"/trials/nct06601504/","file":"src/data/pipeline-trials-wave5.ts","line":162,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L162","field":"yearReported / calendar","current":"2026-05-12","proposed":"2026-05-23","evidence":"Primary completion date moved from 2026-05-12 to 2026-05-23; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06601504","detected":"2026-09-28","id":"trial-completion:nct06601504:yearreported-calendar:2026-05-23"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06660654","entityName":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","entityKind":"trial","route":"/trials/nct06660654/","file":"src/data/pipeline-trials-wave6.ts","line":7765,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7765","field":"yearReported / calendar","current":"2027-09-30","proposed":"2029-12-30","evidence":"Primary completion date moved from 2027-09-30 to 2029-12-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06660654","detected":"2026-09-28","id":"trial-completion:nct06660654:yearreported-calendar:2029-12-30"},{"kind":"trial-status","confidence":"medium","entityId":"nct06736717","entityName":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","entityKind":"trial","route":"/trials/nct06736717/","file":"src/data/spikes/pancreatic-registry-trials.ts","line":861,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/pancreatic-registry-trials.ts#L861","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT06736717","detected":"2026-09-28","id":"trial-status:nct06736717:status:active"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06736717","entityName":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","entityKind":"trial","route":"/trials/nct06736717/","file":"src/data/spikes/pancreatic-registry-trials.ts","line":861,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/pancreatic-registry-trials.ts#L861","field":"yearReported / calendar","current":"2026-07","proposed":"2026-07-16","evidence":"Primary completion date moved from 2026-07 to 2026-07-16; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06736717","detected":"2026-09-28","id":"trial-completion:nct06736717:yearreported-calendar:2026-07-16"},{"kind":"trial-status","confidence":"medium","entityId":"nct06929624","entityName":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","entityKind":"trial","route":"/trials/nct06929624/","file":"src/data/pipeline-trials-wave2.ts","line":985,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L985","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT06929624","detected":"2026-09-28","id":"trial-status:nct06929624:status:active"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06989437","entityName":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","entityKind":"trial","route":"/trials/nct06989437/","file":"src/data/pipeline-trials-wave6.ts","line":7729,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7729","field":"yearReported / calendar","current":"2028-01-17","proposed":"2028-01-23","evidence":"Primary completion date moved from 2028-01-17 to 2028-01-23; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06989437","detected":"2026-09-28","id":"trial-completion:nct06989437:yearreported-calendar:2028-01-23"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07069712","entityName":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","entityKind":"trial","route":"/trials/nct07069712/","file":"src/data/pipeline-trials-wave6.ts","line":5893,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L5893","field":"yearReported / calendar","current":"2027-11-03","proposed":"2027-11-09","evidence":"Primary completion date moved from 2027-11-03 to 2027-11-09; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07069712","detected":"2026-09-28","id":"trial-completion:nct07069712:yearreported-calendar:2027-11-09"},{"kind":"trial-status","confidence":"medium","entityId":"nct07183189","entityName":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","entityKind":"trial","route":"/trials/nct07183189/","file":"src/data/pipeline-trials-wave4.ts","line":566,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L566","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT07183189","detected":"2026-09-28","id":"trial-status:nct07183189:status:active"},{"kind":"trial-status","confidence":"medium","entityId":"nct07266441","entityName":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","entityKind":"trial","route":"/trials/nct07266441/","file":"src/data/pipeline-trials-wave5.ts","line":192,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L192","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT07266441","detected":"2026-09-28","id":"trial-status:nct07266441:status:active"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07405164","entityName":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","entityKind":"trial","route":"/trials/nct07405164/","file":"src/data/pipeline-trials-wave6.ts","line":7645,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7645","field":"yearReported / calendar","current":"2034-01-14","proposed":"2034-04-22","evidence":"Primary completion date moved from 2034-01-14 to 2034-04-22; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07405164","detected":"2026-09-28","id":"trial-completion:nct07405164:yearreported-calendar:2034-04-22"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07419880","entityName":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","entityKind":"trial","route":"/trials/nct07419880/","file":"src/data/spikes/tnbc-registry-trials.ts","line":469,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/tnbc-registry-trials.ts#L469","field":"yearReported / calendar","current":"2027-01-30","proposed":"2027-12-31","evidence":"Primary completion date moved from 2027-01-30 to 2027-12-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07419880","detected":"2026-09-28","id":"trial-completion:nct07419880:yearreported-calendar:2027-12-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07619521","entityName":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","entityKind":"trial","route":"/trials/nct07619521/","file":"src/data/spikes/pancreatic-registry-trials.ts","line":1337,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/pancreatic-registry-trials.ts#L1337","field":"yearReported / calendar","current":"2026-10-30","proposed":"2028-09-08","evidence":"Primary completion date moved from 2026-10-30 to 2028-09-08; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07619521","detected":"2026-09-28","id":"trial-completion:nct07619521:yearreported-calendar:2028-09-08"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07769502","entityName":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatob","entityKind":"trial","route":"/trials/nct07769502/","file":"src/data/spikes/lung-trial-sponsors.ts","line":147,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-trial-sponsors.ts#L147","field":"yearReported / calendar","current":"2028-11","proposed":"2028-09","evidence":"Primary completion date moved from 2028-11 to 2028-09; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07769502","detected":"2026-09-28","id":"trial-completion:nct07769502:yearreported-calendar:2028-09"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04771130","entityName":"A Study of BGB-11417 in Participants With Myeloid Malignancies","entityKind":"trial","route":"/trials/nct04771130/","file":"src/data/pipeline-trials-wave6.ts","line":2449,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L2449","field":"yearReported / calendar","current":"2028-02-08","proposed":"2028-08-31","evidence":"Primary completion date moved from 2028-02-08 to 2028-08-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04771130","detected":"2026-09-17","id":"trial-completion:nct04771130:yearreported-calendar:2028-08-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05262400","entityName":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","entityKind":"trial","route":"/trials/nct05262400/","file":"src/data/pipeline-trials-wave6.ts","line":6061,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L6061","field":"yearReported / calendar","current":"2026-08-23","proposed":"2027-02-26","evidence":"Primary completion date moved from 2026-08-23 to 2027-02-26; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05262400","detected":"2026-09-17","id":"trial-completion:nct05262400:yearreported-calendar:2027-02-26"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05438459","entityName":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","entityKind":"trial","route":"/trials/nct05438459/","file":"src/data/spikes/pancreatic-registry-trials.ts","line":746,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/pancreatic-registry-trials.ts#L746","field":"yearReported / calendar","current":"2028-12-31","proposed":"2032-03-31","evidence":"Primary completion date moved from 2028-12-31 to 2032-03-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05438459","detected":"2026-09-17","id":"trial-completion:nct05438459:yearreported-calendar:2032-03-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06065748","entityName":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","entityKind":"trial","route":"/trials/nct06065748/","file":"src/data/pipeline-trials-wave6.ts","line":1237,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L1237","field":"yearReported / calendar","current":"2027-02-19","proposed":"2028-04-20","evidence":"Primary completion date moved from 2027-02-19 to 2028-04-20; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06065748","detected":"2026-09-17","id":"trial-completion:nct06065748:yearreported-calendar:2028-04-20"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06297226","entityName":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","entityKind":"trial","route":"/trials/nct06297226/","file":"src/data/pipeline-trials-wave5.ts","line":2083,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L2083","field":"yearReported / calendar","current":"2027-06-30","proposed":"2026-07-31","evidence":"Primary completion date moved from 2027-06-30 to 2026-07-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06297226","detected":"2026-09-17","id":"trial-completion:nct06297226:yearreported-calendar:2026-07-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06423911","entityName":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","entityKind":"trial","route":"/trials/nct06423911/","file":"src/data/pipeline-trials-wave3.ts","line":12,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave3.ts#L12","field":"yearReported / calendar","current":"2025-12","proposed":"2027-06-30","evidence":"Primary completion date moved from 2025-12 to 2027-06-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06423911","detected":"2026-09-17","id":"trial-completion:nct06423911:yearreported-calendar:2027-06-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06901531","entityName":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","entityKind":"trial","route":"/trials/nct06901531/","file":"src/data/pipeline-trials-wave6.ts","line":1753,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L1753","field":"yearReported / calendar","current":"2027-03-31","proposed":"2028-09-30","evidence":"Primary completion date moved from 2027-03-31 to 2028-09-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06901531","detected":"2026-09-17","id":"trial-completion:nct06901531:yearreported-calendar:2028-09-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07332000","entityName":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","entityKind":"trial","route":"/trials/nct07332000/","file":"src/data/pipeline-trials-wave5.ts","line":354,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L354","field":"yearReported / calendar","current":"2026-08","proposed":"2027-02","evidence":"Primary completion date moved from 2026-08 to 2027-02; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07332000","detected":"2026-09-17","id":"trial-completion:nct07332000:yearreported-calendar:2027-02"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07367516","entityName":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","entityKind":"trial","route":"/trials/nct07367516/","file":"src/data/pipeline-trials-wave6.ts","line":6007,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L6007","field":"yearReported / calendar","current":"2026-09","proposed":"2027-02","evidence":"Primary completion date moved from 2026-09 to 2027-02; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07367516","detected":"2026-09-17","id":"trial-completion:nct07367516:yearreported-calendar:2027-02"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07551596","entityName":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","entityKind":"trial","route":"/trials/nct07551596/","file":"src/data/spikes/colorectal-registry-trials.ts","line":2355,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-registry-trials.ts#L2355","field":"yearReported / calendar","current":"2026-09-30","proposed":"2029-08-28","evidence":"Primary completion date moved from 2026-09-30 to 2029-08-28; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07551596","detected":"2026-09-17","id":"trial-completion:nct07551596:yearreported-calendar:2029-08-28"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07581002","entityName":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","entityKind":"trial","route":"/trials/nct07581002/","file":"src/data/pipeline-trials-wave6.ts","line":5749,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L5749","field":"yearReported / calendar","current":"2032-05","proposed":"2032-06","evidence":"Primary completion date moved from 2032-05 to 2032-06; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07581002","detected":"2026-09-17","id":"trial-completion:nct07581002:yearreported-calendar:2032-06"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05186974","entityName":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","entityKind":"trial","route":"/trials/nct05186974/","file":"src/data/pipeline-trials-wave5.ts","line":3600,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3600","field":"yearReported / calendar","current":"2026-09","proposed":"2027-03","evidence":"Primary completion date moved from 2026-09 to 2027-03; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05186974","detected":"2026-09-11","id":"trial-completion:nct05186974:yearreported-calendar:2027-03"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05201248","entityName":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th","entityKind":"trial","route":"/trials/nct05201248/","file":"src/data/pipeline-trials-wave5.ts","line":1705,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1705","field":"yearReported / calendar","current":"2025-04","proposed":"2026-09","evidence":"Primary completion date moved from 2025-04 to 2026-09; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05201248","detected":"2026-09-11","id":"trial-completion:nct05201248:yearreported-calendar:2026-09"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05845450","entityName":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","entityKind":"trial","route":"/trials/nct05845450/","file":"src/data/spikes/colorectal-registry-trials.ts","line":1014,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-registry-trials.ts#L1014","field":"yearReported / calendar","current":"2026-05","proposed":"2027-05","evidence":"Primary completion date moved from 2026-05 to 2027-05; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05845450","detected":"2026-09-11","id":"trial-completion:nct05845450:yearreported-calendar:2027-05"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07602855","entityName":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","entityKind":"trial","route":"/trials/nct07602855/","file":"src/data/spikes/lung-registry-trials.ts","line":1574,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L1574","field":"yearReported / calendar","current":"2029-07-05","proposed":"2029-06-21","evidence":"Primary completion date moved from 2029-07-05 to 2029-06-21; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07602855","detected":"2026-09-10","id":"trial-completion:nct07602855:yearreported-calendar:2029-06-21"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07016230","entityName":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri","entityKind":"trial","route":"/trials/nct07016230/","file":"src/data/spikes/lung-registry-trials.ts","line":1748,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L1748","field":"yearReported / calendar","current":"2026-10-18","proposed":"2027-05-18","evidence":"Primary completion date moved from 2026-10-18 to 2027-05-18; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07016230","detected":"2026-09-09","id":"trial-completion:nct07016230:yearreported-calendar:2027-05-18"},{"kind":"trial-status","confidence":"low","entityId":"alkove-1","entityName":"ALKOVE-1","entityKind":"trial","route":"/trials/alkove-1/","file":"src/data/spikes/nsclc.ts","line":120,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/nsclc.ts#L120","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT05384626","id":"trial-status:alkove-1:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"a071401","entityName":"Alliance A071401","entityKind":"trial","route":"/trials/a071401/","file":"src/data/issues-2026-09-wave-b.ts","line":239,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/issues-2026-09-wave-b.ts#L239","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT02523014","id":"trial-status:a071401:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"augment-101","entityName":"AUGMENT-101","entityKind":"trial","route":"/trials/augment-101/","file":"src/data/spikes/aml.ts","line":329,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/aml.ts#L329","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT04065399","id":"trial-status:augment-101:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"nct07670312","entityName":"Evaluation of XYA02 in Patients With Advanced Solid Tumors","entityKind":"trial","route":"/trials/nct07670312/","file":"src/data/spikes/pancreatic-registry-trials.ts","line":266,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/pancreatic-registry-trials.ts#L266","field":"status","current":"planned","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded planned. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT07670312","id":"trial-status:nct07670312:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"firefly-1","entityName":"FIREFLY-1","entityKind":"trial","route":"/trials/firefly-1/","file":"src/data/paediatric-fronts.ts","line":31,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/paediatric-fronts.ts#L31","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT04775485","id":"trial-status:firefly-1:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"harmoni-3","entityName":"HARMONi-3","entityKind":"trial","route":"/trials/harmoni-3/","file":"src/data/spikes/nsclc.ts","line":73,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/nsclc.ts#L73","field":"status","current":"mixed","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded mixed. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT05899608","id":"trial-status:harmoni-3:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"linker-mm1","entityName":"LINKER-MM1","entityKind":"trial","route":"/trials/linker-mm1/","file":"src/data/spikes/multiple-myeloma.ts","line":226,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/multiple-myeloma.ts#L226","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT03761108","id":"trial-status:linker-mm1:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"monumental-1","entityName":"MonumenTAL-1","entityKind":"trial","route":"/trials/monumental-1/","file":"src/data/spikes/multiple-myeloma.ts","line":219,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/multiple-myeloma.ts#L219","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT04634552","id":"trial-status:monumental-1:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"niche-2","entityName":"NICHE-2","entityKind":"trial","route":"/trials/niche-2/","file":"src/data/spikes/colorectal-molecular.ts","line":928,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-molecular.ts#L928","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT03026140","id":"trial-status:niche-2:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"partner","entityName":"PARTNER","entityKind":"trial","route":"/trials/partner/","file":"src/data/spikes/tnbc-treatment.ts","line":471,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/tnbc-treatment.ts#L471","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT03150576","id":"trial-status:partner:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"nct07271355","entityName":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,","entityKind":"trial","route":"/trials/nct07271355/","file":"src/data/spikes/colorectal-registry-trials.ts","line":624,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-registry-trials.ts#L624","field":"status","current":"planned","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded planned. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT07271355","id":"trial-status:nct07271355:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"hr-nbl1","entityName":"SIOPEN HR-NBL1","entityKind":"trial","route":"/trials/hr-nbl1/","file":"src/data/spikes/neuroblastoma.ts","line":132,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/neuroblastoma.ts#L132","field":"status","current":"mixed","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded mixed. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT01704716","id":"trial-status:hr-nbl1:status:recruiting","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"soho-01","entityName":"SOHO-01","entityKind":"trial","route":"/trials/soho-01/","file":"src/data/spikes/nsclc.ts","line":126,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/nsclc.ts#L126","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT05099172","id":"trial-status:soho-01:status:recruiting","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Nezglyal","field":"new drug record","current":"(not in corpus)","proposed":"add product leriglitazone (Nezglyal) with the EU status the register page shows","evidence":"EMA register: Nezglyal (leriglitazone) Authorised, 2026-09-21. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2026-09-21, opinion Positive 2026-07-23.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/nezglyal","reason":"no corpus product is named exactly leriglitazone / leriglitazone / Nezglyal","id":"new-product:nezglyal:new-drug-record:add-product-leriglitazone-nezglyal-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Waskyra","field":"new drug record","current":"(not in corpus)","proposed":"add product etuvetidigene autotemcel (Waskyra) with the EU status the register page shows","evidence":"EMA register: Waskyra (etuvetidigene autotemcel) Authorised, 2026-01-09. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2026-01-09.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/waskyra","reason":"no corpus product is named exactly etuvetidigene autotemcel / genetically modified autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human Wiskott-Aldrich Syndrome (WAS) gene / Waskyra","id":"new-product:waskyra:new-drug-record:add-product-etuvetidigene-autotemcel-waskyra-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Lynkuet","field":"new drug record","current":"(not in corpus)","proposed":"add product elinzanetant (Lynkuet) with the EU status the register page shows","evidence":"EMA register: Lynkuet (elinzanetant) Authorised, 2025-11-17. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2025-11-17.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/lynkuet","reason":"no corpus product is named exactly elinzanetant / elinzanetant / Lynkuet","id":"new-product:lynkuet:new-drug-record:add-product-elinzanetant-lynkuet-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Casgevy","field":"new drug record","current":"(not in corpus)","proposed":"add product exagamglogene autotemcel (Casgevy) with the EU status the register page shows","evidence":"EMA register: Casgevy (exagamglogene autotemcel) Authorised, 2024-02-09. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2024-02-09.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/casgevy","reason":"no corpus product is named exactly exagamglogene autotemcel / Exagamglogene autotemcel / Casgevy","id":"new-product:casgevy:new-drug-record:add-product-exagamglogene-autotemcel-casgevy-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Libmeldy","field":"new drug record","current":"(not in corpus)","proposed":"add product autologous CD34+ cells encoding ARSA gene (Libmeldy) with the EU status the register page shows","evidence":"EMA register: Libmeldy (autologous CD34+ cells encoding ARSA gene) Authorised, 2020-12-17. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2020-12-17.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy","reason":"no corpus product is named exactly autologous CD34+ cells encoding ARSA gene / atidarsagene autotemcel / Libmeldy","id":"new-product:libmeldy:new-drug-record:add-product-autologous-cd34-cells-encoding-arsa-gene-libmeldy-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Lumeblue (previously Methylthioninium chloride Cosmo)","field":"new drug record","current":"(not in corpus)","proposed":"add product methylthioninium chloride (Lumeblue (previously Methylthioninium chloride Cosmo)) with the EU status the register page shows","evidence":"EMA register: Lumeblue (previously Methylthioninium chloride Cosmo) (methylthioninium chloride) Authorised, 2020-08-19. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2020-08-19.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/lumeblue","reason":"no corpus product is named exactly methylthioninium chloride / methylthioninium chloride / Lumeblue (previously Methylthioninium chloride Cosmo)","id":"new-product:lumeblue-previously-methylthioninium-chloride-cosmo-:new-drug-record:add-product-methylthioninium-chloride-lumeblue-previously-methylthioninium-chlo","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Xromi","field":"new drug record","current":"(not in corpus)","proposed":"add product hydroxycarbamide (Xromi) with the EU status the register page shows","evidence":"EMA register: Xromi (hydroxycarbamide) Authorised, 2019-07-01. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2019-07-01.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/xromi","reason":"no corpus product is named exactly hydroxycarbamide / hydroxycarbamide / Xromi","id":"new-product:xromi:new-drug-record:add-product-hydroxycarbamide-xromi-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"SomaKit TOC","field":"new drug record","current":"(not in corpus)","proposed":"add product edotreotide (SomaKit TOC) with the EU status the register page shows","evidence":"EMA register: SomaKit TOC (edotreotide) Authorised, 2016-12-08. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2016-12-08.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/somakit-toc","reason":"no corpus product is named exactly edotreotide / edotreotide / SomaKit TOC","id":"new-product:somakit-toc:new-drug-record:add-product-edotreotide-somakit-toc-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Strimvelis","field":"new drug record","current":"(not in corpus)","proposed":"add product autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence (Strimvelis) with the EU status the register page shows","evidence":"EMA register: Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) Authorised, 2016-05-26. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2016-05-26.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis","reason":"no corpus product is named exactly autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence / autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells / Strimvelis","id":"new-product:strimvelis:new-drug-record:add-product-autologous-cd34-enriched-cell-fraction-that-contains-cd34-cells-transduced-with-retroviral-vector-that-encode","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Entyvio","field":"new drug record","current":"(not in corpus)","proposed":"add product vedolizumab (Entyvio) with the EU status the register page shows","evidence":"EMA register: Entyvio (vedolizumab) Authorised, 2014-05-22. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2014-05-22.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio","reason":"no corpus product is named exactly vedolizumab / vedolizumab / Entyvio","id":"new-product:entyvio:new-drug-record:add-product-vedolizumab-entyvio-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Procysbi","field":"new drug record","current":"(not in corpus)","proposed":"add product mercaptamine (Procysbi) with the EU status the register page shows","evidence":"EMA register: Procysbi (mercaptamine) Authorised, 2013-09-05. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2013-09-05.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi","reason":"no corpus product is named exactly mercaptamine / mercaptamine bitartrate / Procysbi","id":"new-product:procysbi:new-drug-record:add-product-mercaptamine-procysbi-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"NeoRecormon","field":"new drug record","current":"(not in corpus)","proposed":"add product epoetin beta (NeoRecormon) with the EU status the register page shows","evidence":"EMA register: NeoRecormon (epoetin beta) Authorised, 1997-07-16. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 1997-07-16.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon","reason":"no corpus product is named exactly epoetin beta / epoetin beta / NeoRecormon","id":"new-product:neorecormon:new-drug-record:add-product-epoetin-beta-neorecormon-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Cystagon","field":"new drug record","current":"(not in corpus)","proposed":"add product mercaptamine bitartrate (Cystagon) with the EU status the register page shows","evidence":"EMA register: Cystagon (mercaptamine bitartrate) Authorised, 1997-06-23. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 1997-06-23.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/cystagon","reason":"no corpus product is named exactly mercaptamine bitartrate / mercaptamine bitartrate / Cystagon","id":"new-product:cystagon:new-drug-record:add-product-mercaptamine-bitartrate-cystagon-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Yartemlea","field":"new drug record","current":"(not in corpus)","proposed":"add product Narsoplimab (Yartemlea) with the EU status the register page shows","evidence":"EMA register: Yartemlea (Narsoplimab) Opinion under re-examination. Register page: \"Opinion under re-examination: EMA is re-examining this opinion on request of the applicant\", opinion Negative 2026-06-25.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/yartemlea","reason":"no corpus product is named exactly Narsoplimab / narsoplimab / Yartemlea","id":"new-product:yartemlea:new-drug-record:add-product-narsoplimab-yartemlea-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"new-product","confidence":"low","entityName":"Zefylti","field":"new drug record","current":"(not in corpus)","proposed":"add product filgrastim (Zefylti) with the EU status the register page shows","evidence":"EMA register: Zefylti (filgrastim) Application withdrawn. Register page: \"Application withdrawn: The application for this medicine has been withdrawn\".","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/zefylti-0","reason":"no corpus product is named exactly filgrastim / filgrastim / Zefylti (the snapshot's nearest name was filgrastim, a partial match)","id":"new-product:zefylti:new-drug-record:add-product-filgrastim-zefylti-with-the-eu-status-the-register-page-shows","detected":"2026-10-03"},{"kind":"trial-status","confidence":"low","entityId":"tiragolumab","entityName":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (NCT04543617)","entityKind":"trial","route":"/drugs/tiragolumab/","field":"new trial record","current":"(not in corpus)","proposed":"add phase 3 trial NCT04543617 for Tiragolumab with status completed","evidence":"A phase 3 study of Tiragolumab moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-09-17).","sourceUrl":"https://clinicaltrials.gov/study/NCT04543617","detected":"2026-09-17","id":"trial-status:tiragolumab:new-trial-record:add-phase-3-trial-nct04543617-for-tiragolumab-with-status-completed"}],"auto":{"rows":[],"alreadyOnMain":0}}